Latest Commercialisation Strategy News

Papyrus Australia has marked significant progress in July 2025 with successful testing at its Rapid Prototyping facility and advancing plans for a commercial production site, while also writing down key investments.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

Rhythm Biosciences has formalised a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneType Breast Cancer Risk Assessment Test, expanding access to early detection tools for women in the US and Australia.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

Impact Minerals’ 50%-owned Alluminous Pty Ltd advances its proprietary HiPurA® High Purity Alumina technology with new leadership and pilot plant commissioning, attracting strong customer interest.

AnteoTech has appointed Merrill Gray as its new Managing Director and CEO following a successful interim period, while issuing over 22 million shares to staff under its FY2025 incentive program.

AnteoTech has mutually terminated its A$1.4 million Queensland government grant to avoid costly co-investment, opting instead for cheaper third-party testing to advance its Ultranode™ battery technology.

Green360 Technologies has successfully raised A$4 million through a share placement to fund the commercialisation and scaling of its innovative low-carbon cement technology, supported by institutional investors and strengthened leadership.

Papyrus Australia appoints Daniel Schmidt as CEO to lead its transition from R&D to commercial operations, alongside a strategic restructure to support growth.

EBR Systems has won final CMS approval for New Technology Add-On Payment reimbursement, paving the way for Medicare coverage of its innovative WiSE cardiac pacing system starting October 2025.

Nanollose Limited has completed a successful pilot manufacturing run blending its Nullarbor-20 fibre with wool, raised $1.05 million through an entitlement issue, and appointed Andrew Moullin as CEO to drive its commercialisation strategy.